trASO™ for easy and reliable ASO quantification
Works directly in complex biological media
Eliminate noise from varying extraction efficiencies.
Fast and simple workflow
Minimal protocol steps and measurement on a fluorescence plate-reader.
Built for ASOs
Overcomes limitations of other techniques posed by sequence length.
Suits a wide variety of chemical modifications.
Including standard Phosphorothioate (PS), 2’-O-Methoxyethyl (MOE), 2’-O-Methyl (OMe) modifications.
Introducing trASO™
trASO™ offers quantification Antisense Oligonucleotide Therapies (ASOs) directly in biological samples such as blood serum. Developed using Nanovery's patented Nucleic Acid Nanorobotics (NANs) platform, trASO™ comes in the form of a reagent, offering an enzyme-free and isothermal assay format designed for simplicity and reliability. trASO™ can be easily tailored to support a range of ADME and pharmacokinetic (PK) studies in bioanalysis, with the flexibility to accommodate various ASO patterns (such as Antagomir, Gapmer, ssDNA), chemical modifications, and sample types.
trASO™ compared to standard quantification techniques
Specific metabolite detection
Dynamic range
ICH-M10 (chromatography) guidelines
High throughput
ICH-M10 (ligand binding assay) guidelines
Direct to sample
Low sample volume required
Direct to sample
Simple protocol
Robust and reproducible
Low working volume
Poor sensitivity
High cost
Requires re-optimisation between projects/targets
Poor specificity
Robustness and reproducibility issues
Low throughput
Multiple washing steps
Robustness and reproducibility
No regulatory guidelines
Laborious purification protocol
Requires splint ligation reaction and extensive optimisation
No regulatory guidelines
Experiencing these issues in PK assays for antisense oligonucleotides?
Chemical modifications
ASOs are chemically modified to boost their stability, uptake and target affinity. These modifications, including additional moieties for stability, targeting, and biodistribution, also interfere with the efficiency of enzymatic processes in qPCR, leading to inconsistencies in quantification.
trASO™ assay is based on our proprietary NAN technology. It is distinctively enzyme-free and relies on nucleic acid hybridisation and strand displacement reactions, which makes it excel at consistently detecting ASOs. Read more about our technology (here).
RNA extraction efficiency
Long assay development times
Complex and Costly Equipment and protocols
Speak with our ASO Specialist
Our results
Our DNA nanorobots demonstrate remarkable compatibility with chemical modifications, offering robust detection and precise quantification of antisense oligonucleotides. We validate the ASO detection and quantification assay in line with ICH-M10 guidelines to guarantee high levels of accuracy, precision, and selectivity across biological matrices. You can find our full collection of validation data here.
Proven performance of trASO™
The results below illustrate the robust detection capabilities of NANs across four sample types: 1) DNA, 2) RNA, and ASOs with 3) OMe, and 4) MOE modifications. These assays demonstrate excellent linear responses, enabling precise quantification within the low picomolar range. Small error bars indicate high accuracy, and the simplicity of data analysis highlights the practical efficacy of our technology in various bioanalytical settings.
Order custom ASO assay
- Discuss your project requirements with our expert team.
- We will evaluate your ASO's characteristics.
- Our team will prepare a proposal tailored to meet your needs.
- Get a complimentary evaluation license with every assay we develop.
Get detailed specs
Discover the precision and efficiency of the trASO™ assay with our detailed specs and case studies.
Learn how our technology is transforming ASO bioanalysis, offering a significant leap in simplicity and performance over alternative methods. Access our recent materials now to unlock the full potential of your research and development.